

CLAIMS**ANTIANGIOGENIC ACTIVE IMMUNOTHERAPY.**

- 5 1. Method for active vaccination characterized by the administration of a vaccine preparation, adjuvated or not, comprising polypeptides and/or oligonucleotides coding for proteins directly associated to an increment of the angiogenesis, and variants thereof.
- 10 2. Method according to claim 1, wherein the proteins directly associated to an increment in angiogenesis belong to the family of the Vascular Endothelial Growth Factor (VEGF).
- 15 3. Method according to claims 1 and 2, wherein the protein is one of the VEGFA isoforms.
- 20 4. Method according to claims 1, 2, and 3, wherein the protein is the VEGFA 121.
- 25 5. Method according to claims 1, 2, and 3, wherein the protein is the VEGFA 165.
- 30 6. Method according to claims 1, 2, and 3, wherein the protein is the VEGFA 189.
- 35 7. Method according to claims 1 and 2, wherein the protein is one of the VEGFB isoforms.
- 40 8. Method according to claims 1, 2 and 7, wherein the protein is the VEGFB 167.
- 45 9. Method according to claims 1 and 2, wherein the protein is the VEGFC.
- 50 10. Method according to claims 1 and 2, wherein the protein is the VEGFD.
- 55 11. Method according to claims 1 and 2, wherein the protein is the PLGF.
- 60 12. Method according to claim 1, wherein the proteins directly associated to an increment in angiogenesis belong to the group of receptors and co-receptors of the VEGF.
- 65 13. Method according to claims 1 and 12, wherein the protein is the VEGFR1.
- 70 14. Method according to claims 1 and 12, wherein the protein is the VEGFR2.
- 75 15. Method according to claims 1 and 12, wherein the protein is the VEGFR3.
- 80 16. Method according to claims 1 and 12, wherein the protein is the NRP1.
- 85 17. Method according to claims 1 and 12, wherein the protein is the NRP2.
- 90 18. Method according to claims from 1 to 17, wherein the immunogens are mutants derived from human VEGF family or their receptors.

19. Method according to claims from 1 to 18, wherein the antigens are of autologous nature.
20. Method according to claims from 1 to 18, wherein the antigens are of heterologous nature.
- 5 21. Method according to claims from 1 to 20, wherein the immunogens are synthetic, recombinants, chimeric or natural.
22. Method according to claims from 1 to 21, wherein the immunogens are of peptidic nature.
- 10 23. Method according to claim 1, wherein the immunogens are a mixture of at least two of the molecules described in claims from 2 to 22.
24. Method according to claims from 1 to 23, for the treatment of tumors in mammals.
25. Method according to claims from 1 to 23, for the treatment and prevention of tumors in humans.
- 15 26. Method according to claims from 1 to 23, for the treatment of diseases characterized by an increment in the angiogenesis, as in malignant neoplasia and their metastasis in humans.
27. Method according to claims from 1 to 23, for the treatment of entities characterized by an increase in the angiogenesis, as occurs in benign neoplasia.
- 20 28. Method according to claims from 1 to 23, for the treatment of diseases characterized by an increment in the angiogenesis, as occurs in acute and chronic inflammatory processes.
29. Method according to claims from 1 to 23, for the treatment of diseases characterized by an increment in the angiogenesis, as occurs in autoimmune processes.
- 25 30. Method according to claims from 1 to 23, for the treatment of diseases characterized by an increment in the angiogenesis, as occurs in ocular alterations.
31. Method according to claims from 1 to 23, for the treatment of diseases characterized by an increment in the angiogenesis, specifically in affective animals and cattle.
32. A vaccine composition comprising polypeptides and/or oligonucleotides coding for proteins directly associated to an increment of the angiogenesis, and variants thereof, administered in the presence or not of a pharmaceutically accepted adjuvant

33. A vaccine composition according to claim 32, wherein the associated protein is the Vascular Endothelial Growth Factor (VEGF)
34. A vaccine composition according to claims 32, and 33, wherein the associated protein is one of the VEGFA isoforms.
- 5 35. A vaccine composition according to claims 32, 33, and 34, wherein the associated protein is the VEGFA 121.
36. A vaccine composition according to claims 32, 33 and 34, wherein the associated protein is the VEGFA 165.
- 10 37. A vaccine composition according to claims 32, 33 and 34, wherein the associated protein is the VEGFA 189.
38. A vaccine composition according to claims 32 and 33, wherein the associated protein is one of the VEGFB isoforms.
39. A vaccine composition according to claims 32, 33 and 38, wherein the associated protein is the VEGFB 167.
- 15 40. A vaccine composition according to claims 32, and 33, wherein the associated protein is the VEGFC .
41. A vaccine composition according to claims 32, and 33, wherein the associated protein is the VEGFD.
42. A vaccine composition according to claims 32, and 33, wherein the associated protein is the PIGF
- 20 43. A vaccine composition according to claim 32, wherein the associated protein belongs to the group of VEGF receptors and co-receptors
44. A vaccine composition according to claims 32, and 43, wherein the associated protein is the VEGFR1.
45. A vaccine composition according to claims 32, and 43, wherein the associated protein is the VEGFR2.
- 25 46. A vaccine composition according to claims 32, and 43, wherein the associated protein is the VEGFR3.
47. A vaccine composition according to claims 32, and 43, wherein the associated protein is the NRP1.
- 30 48. A vaccine composition according to claims 32, and 43, wherein the associated protein is the NRP2.
49. A vaccine composition according to claims from 32 to 48, characterized by containing as immunogens mutants derived from human VEGF family, their receptors and co-receptors
- 35 50. A vaccine composition according to claims from 32 to 49, wherein the antigens are of autologous nature.

51. A vaccine composition according to claims from 32 to 49, wherein the antigens are of heterologous nature.
52. A vaccine composition according to claims from 32 to 51, wherein the immunogens are synthetic, recombinant, chimeric or natural.
- 5 53. A vaccine composition according to claims from 32 to 51, wherein the immunogens are of peptidic nature.
54. A vaccine composition according to claim 32 characterized by comprising as immunogens a mixture of at least two of the molecules described in claims from 33 to 53.
- 10 55. A vaccine composition according to claims from 32 to 54 wherein the immunogen is administered as part of plasmidic vectors.
56. A vaccine composition according to claims from 32 to 54 wherein the immunogen is administered as part of viral vectors.
- 15 57. A vaccine composition according to claims from 32 to 54 wherein the immunogen is administered as a polypeptide.
58. A vaccine composition according to claims from 32 to 57 wherein the immunogen is administered associated covalently or not to an adjuvant.
- 15 59. A vaccine composition according to claim 58, wherein the adjuvant is particulate.
- 20 60. A vaccine composition according to claim 59, wherein the adjuvant is specifically the recombinant particle of Hepatitis B Core Antigen.
61. A vaccine composition according to claim 59, wherein the adjuvant is specifically the recombinant particle of Hepatitis C Core Antigen.
- 25 62. A vaccine composition according to claim 59, wherein the adjuvant is specifically VSSP.
63. A vaccine composition according to claim 58, wherein the adjuvant is of protein nature.
64. A vaccine composition according to claim 63, wherein the adjuvant is the OPC protein.
- 30 65. A vaccine composition according to claim 63, wherein the adjuvant is the KLH protein.
66. A vaccine composition according to claim 58, wherein the adjuvant is an emulsion.
- 35 67. A vaccine composition according to claim 66, wherein the adjuvant is the Freund adjuvant or its derivatives.
68. A vaccine composition according to claim 66, wherein the adjuvant is Montanide ISA 51.